MedTrace Logo

HIFU for Focal Ablation of Prostate Tissue: An Observational Study

NCT03620786 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2026-04-16

No results posted yet for this study

Summary

The Sonablate HIFU device was approved by the U.S.FDA for prostate tissue ablation in October, 2015. The purpose of this observational research study is to investigate the localized treatment of prostate cancer using HIFU through clinical data and health-related quality of life (HRQOL) questionnaires.

Conditions

Interventions

DEVICE

Sonablate HIFU device

In this study, we will be using the Sonablate 450 HIFU System. The Sonablate HIFU device was approved by the U.S. FDA for prostate tissue ablation in October, 2015. HIFU is an example of focal therapy, where the intervention involves targeting diseased areas of prostate tissue, while preserving healthy prostate tissue and minimizing damage to surrounding structures.

Sponsors & Collaborators

Principal Investigators

  • Leonard Marks, MD · University of California, Los Angeles

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-26
Primary Completion
2027-01-31
Completion
2028-01-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03620786 on ClinicalTrials.gov